What is claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, $-(C_1\text{-}C_{10})alkyl$, $-C(O)R_9$, or $-C(O)NHR_9$;

R_5 is -H or -(C_1-C_{10})alkyl;

R_6 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl,-(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -COR$_{10}$, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -S(O)$_2$$R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

2. The compound of claim 1, wherein:

n is 0;

m is 0; and

R_6 is phenyl.

3. The compound of claim 2, wherein the R_6 phenyl is unsubstituted.

4. The compound of claim 2, wherein the R_6 phenyl is substituted at the para-position.

5. The compound of claim 4, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

6. The compound of claim 5, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

7. The compound of claim 5, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

8. The compound of claim 4, wherein the phenyl is substituted with a -CF_3 group.

9. The compound of claim 1, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_6 is phenyl.

10. The compound of claim 9, wherein the R_6 phenyl is unsubstituted.

11. The compound of claim 9, wherein the R_6 phenyl is substituted at the para-position.

12. The compound of claim 11, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

13. The compound of claim 12, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

14. The compound of claim 12, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

15. The compound of claim 11, wherein the R_6 phenyl is substituted with a -CF_3 group.

16. The compound of claim 1, wherein R_4 is -H.

17. The compound of claim 1, wherein R_4 is -(C_1-C_{10})alkyl.

18. The compound of claim 1, wherein R_4 is -C(O)R_9.

19. The compound of claim 1, wherein R_4 is -C(O)NHR_9.

20. A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, $-(C_1\text{-}C_{10})alkyl$, $-C(O)R_9$, or $-C(O)NHR_9$;

R_5 is -H or $-(C_1\text{-}C_{10})alkyl$;

R_6 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl,-(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -COR_{10}, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -S(O)$_2$$R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

p is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

21. The compound of claim 20, wherein:

p is 0;

m is 0; and

R_6 is phenyl.

22. The compound of claim 21, wherein the R_6 phenyl is unsubstituted.

23. The compound of claim 21, wherein the R_6 phenyl is substituted at the para-position.

24. The compound of claim 23, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

25. The compound of claim 24, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

26. The compound of claim 24, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

27. The compound of claim 23, wherein the R_6 phenyl is substituted with a -CF_3 group.

28. The compound of claim 20, wherein:

p is 0;
m is 1;
R_3 is methyl; and
R_6 is phenyl.

29. The compound of claim 28, wherein the R_6 phenyl is unsubstituted.

30. The compound of claim 28, wherein the R_6 phenyl is substituted at the para-position.

31. The compound of claim 30, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

32. The compound of claim 31, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

33. The compound of claim 31, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

34. The compound of claim 30, wherein the R_6 phenyl is substituted with a -CF_3 group.

35. The compound of claim 20, wherein R_4 is -H.

36. The compound of claim 20, wherein R_4 is -(C_1-C_{10})alkyl.

37. The compound of claim 20 wherein R_4 is -C(O)R_9.

38. The compound of claim 20, wherein R_4 is -C(O)NHR_9.

39. A compound of formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, $-(C_1\text{-}C_{10})alkyl$, $-C(O)R_9$, or $-C(O)NHR_9$;

R_5 is -H or $-(C_1\text{-}C_{10})alkyl$;

R_6 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl,-(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -COR$_{10}$, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -S(O)$_2$$R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

p is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

40. The compound of claim 39, wherein:

p is 0;

m is 0; and

R_6 is phenyl.

41. The compound of claim 40, wherein the R_6 phenyl is unsubstituted.

42. The compound of claim 40, wherein the R_6 phenyl is substituted at the para-position.

43. The compound of claim 42, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

44. The compound of claim 43, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

45. The compound of claim 43, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

46. The compound of claim 42, wherein the R_6 phenyl is substituted with a -CF_3 group.

47. The compound of claim 39, wherein:

p is 0;
m is 1;
R_3 is methyl; and
R_6 is phenyl.

48. The compound of claim 47, wherein the R_6 phenyl is unsubstituted.

49. The compound of claim 47, wherein the R_6 phenyl is substituted at the para-position.

50. The compound of claim 49, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

51. The compound of claim 50, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

52. The compound of claim 50, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

53. The compound of claim 49, wherein the R_6 phenyl is substituted with a -CF_3 group.

54. The compound of claim 39, wherein R_4 is -H.

55. The compound of claim 39, wherein R_4 is -(C_1-C_{10})alkyl.

56. The compound of claim 39, wherein R_4 is -C(O)R_9.

57. The compound of claim 39, wherein R_4 is -C(O)NHR_9.

58. A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$ or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, $-(C_1\text{-}C_{10})alkyl$, $-C(O)R_9$, or $-C(O)NHR_9$;

R_5 is -H or $-(C_1\text{-}C_{10})alkyl$;

R_6 is:

(a) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl,-(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(b) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -C(O)R_{10}, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -S(O)$_2$$R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each halo is independently -F, -Cl, -Br, or -I;

p is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

59. The compound of claim 58, wherein:

p is 0;

m is 0; and

R_6 is phenyl.

60. The compound of claim 59, wherein the R_6 phenyl is unsubstituted.

61. The compound of claim 59, wherein the R_6 phenyl is substituted at the para-position.

62. The compound of claim 61, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

63. The compound of claim 62, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

64. The compound of claim 62, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

65. The compound of claim 61, wherein the R_6 phenyl is substituted with a -CF_3 group.

66. The compound of claim 58, wherein:

p is 0;

m is 1;

R_3 is methyl; and

R_6 is phenyl.

67. The compound of claim 66, wherein the R_6 phenyl is unsubstituted.

68. The compound of claim 66, wherein the R_6 phenyl is substituted at the para-position.

69. The compound of claim 68, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

70. The compound of claim 69, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

71. The compound of claim 69, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

72. The compound of claim 68, wherein the R_6 phenyl is substituted with a -CF_3 group.

73. The compound of claim 58, wherein R_4 is -H.

74. The compound of claim 58, wherein R_4 is -(C_1-C_{10})alkyl.

75. The compound of claim 58, wherein R_4 is -C(O)R_9.

76. The compound of claim 58, wherein R_4 is -C(O)NHR_9.

77. A compound of formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

R_1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, $-(C_1\text{-}C_{10})$alkyl, $-C(O)R_9$, or $-C(O)NHR_9$;

R_5 is -H or $-(C_1\text{-}C_{10})$alkyl;

R_6 is:

(a) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl,$-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(b) -phenyl, -naphthyl, $-(C_{14})$aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_7 and R_8 is independently $-(C_1\text{-}C_6)$alkyl, $-(C_2\text{-}C_6)$alkenyl, $-(C_2\text{-}C_6)$alkynyl, $-(C_3\text{-}C_8)$cycloalkyl, $-(C_5\text{-}C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle,

$-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_{10})_2$, $-CH{=}NR_{10}$, $-NR_{10}OH$, $-OR_{10}$, $-COR_{10}$, $-C(O)OR_{10}$, $-OC(O)R_{10}$, $-OC(O)OR_{10}$, $-SR_{10}$, $-S(O)R_{10}$, or $-S(O)_2R_{10}$;

each R_9 is -H, $-(C_1\text{-}C_6)$alkyl, $-(C_2\text{-}C_6)$alkenyl, $-(C_2\text{-}C_6)$alkynyl, $-(C_3\text{-}C_8)$cycloalkyl, $-(C_5\text{-}C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -OH, $-N(R_{10})_2$, $-CH{=}NR_{10}$, $-NR_{10}OH$, $-OR_{10}$, or $-SR_{10}$;

each R_{10} is independently -H, $-(C_1\text{-}C_6)$alkyl, $-(C_2\text{-}C_6)$alkenyl, $-(C_2\text{-}C_6)$alkynyl, $-(C_3\text{-}C_8)$cycloalkyl, $-(C_5\text{-}C_8)$cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each halo is independently -F, -Cl, -Br, or -I; and

m is an integer ranging from 0 to 2.

78. The compound of claim 77, wherein:

m is 0; and

R_6 is phenyl.

79. The compound of claim 78, wherein the R_6 phenyl is unsubstituted.

80. The compound of claim 78, wherein the R_6 phenyl is substituted at the para-position.

81. The compound of claim 80, wherein the R_6 phenyl is substituted with a $-(C_1\text{-}C_6)$ alkyl group.

82. The compound of claim 81, wherein the $-(C_1\text{-}C_6)$ alkyl group is a *tert*-butyl group.

83. The compound of claim 81, wherein the $-(C_1\text{-}C_6)$ alkyl group is an *iso*-propyl group.

84. The compound of claim 80, wherein the R_6 phenyl is substituted with a $-CF_3$ group.

85. The compound of claim 77, wherein:

m is 1;

R_3 is methyl; and

R_6 is phenyl.

86. The compound of claim 85, wherein the R_6 phenyl is unsubstituted.

87. The compound of claim 85, wherein the R_6 phenyl is substituted at the para-position.

88. The compound of claim 87, wherein the R_6 phenyl is substituted with a -(C_1-C_6) alkyl group.

89. The compound of claim 88, wherein the -(C_1-C_6) alkyl group is a *tert*-butyl group.

90. The compound of claim 88, wherein the -(C_1-C_6) alkyl group is an *iso*-propyl group.

91. The compound of claim 87, wherein the R_6 phenyl is substituted with a -CF_3 group.

92. The compound of claim 77, wherein R_4 is -H.

93. The compound of claim 77, wherein R_4 is -(C_1-C_{10})alkyl.

94. The compound of claim 77, wherein R_4 is -C(O)R_9.

95. The compound of claim 77, wherein R_4 is -C(O)NHR_9.

96. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

97. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 20 and a pharmaceutically acceptable carrier or excipient.

98. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 39 and a pharmaceutically acceptable carrier or excipient.

99. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 58 and a pharmaceutically acceptable carrier or excipient.

100. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 77 and a pharmaceutically acceptable carrier or excipient.

101. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

102. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 20.

103. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 39.

104. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 58.

105. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 77.

106. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

107. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 20.

108. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 39.

109. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 58.

110. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 77.

111. The compound of claim 1, wherein m is 1 and R_3 is attached to a carbon atom adjacent to the nitrogen atom attached to the -C(=N-OR_4)-NR_5R_6 group.

112. The compound of claim 111, wherein the carbon atom to which R_3 is attached is in the (R) configuration.

113. The compound of claim 112, wherein R_3 is -CH_3, -CF_3, or -CH_2CH_3.

114. The compound of claim 20, wherein m is 1 and R_3 is attached to a carbon atom adjacent to the nitrogen atom attached to the -C(=N-OR_4)-NR_5R_6 group.

115. The compound of claim 114, wherein the carbon atom to which R_3 is attached is in the (R) configuration.

116. The compound of claim 115, wherein R_3 is -CH_3, -CF_3, or -CH_2CH_3.

117. The compound of claim 39, wherein m is 1 and R_3 is attached to a carbon atom adjacent to the nitrogen atom attached to the -C(=N-OR_4)-NR_5R_6 group.

118. The compound of claim 117, wherein the carbon atom to which R_3 is attached is in the (R) configuration.

119. The compound of claim 118, wherein R_3 is -CH_3, -CF_3, or -CH_2CH_3.

120. The compound of claim 58, wherein m is 1 and R_3 is attached to a carbon atom adjacent to the nitrogen atom attached to the -C(=N-OR_4)-NR_5R_6 group.

121. The compound of claim 120, wherein the carbon atom to which R_3 is attached is in the (R) configuration.

122. The compound of claim 121, wherein R_3 is -CH_3, -CF_3, or -CH_2CH_3.

123. The compound of claim 77, wherein m is 1 and R_3 is attached to a carbon atom adjacent to the nitrogen atom attached to the $-C(=N-OR_4)-NR_5R_6$ group.

124. The compound of claim 123, wherein the carbon atom to which R_3 is attached is in the (R) configuration.

125. The compound of claim 124, wherein R_3 is $-CH_3$, $-CF_3$, or $-CH_2CH_3$.

126. A compound of formula:



(VI)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_1 is


,

,

,

,

or ;

Ar_2 is



R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, -(C_1-C_{10})alkyl, -C(O)R_9, or -C(O)NHR_9;

R_5 is -H or -(C_1-C_{10})alkyl;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -COR_{10}, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -$S(O)_2R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_{11} and R_{12} is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_7)$_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -$S(O)_2R_7$;

each R_{13} is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3–C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, CH_2(halo), or -halo;

each halo is independently -F, -Cl, -Br, or -I;

s is an integer ranging from 0 to 4;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

t is an integer ranging from 0 to 2;

p is an integer ranging from 0 to 2;

n is an integer ranging from 0 to 3; and

m is an integer ranging from 0 to 2.

127. A compound of formula:



(VII)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_1 is


,

,

,

,

or ;

Ar_2 is



R_1 is -H, -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})aryl$, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, NO_2, $-O(C_1\text{-}C_6)alkyl$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})alkyl$, $-(C_2\text{-}C_{10})alkenyl$, $-(C_2\text{-}C_{10})alkynyl$, $-(C_3\text{-}C_{10})cycloalkyl$, $-(C_8\text{-}C_{14})bicycloalkyl$, $-(C_8\text{-}C_{14})tricycloalkyl$, $-(C_5\text{-}C_{10})cycloalkenyl$, $-(C_8\text{-}C_{14})bicycloalkenyl$, $-(C_8\text{-}C_{14})tricycloalkenyl$, -(3- to 7-membered)heterocycle, or -(7- to 10-

membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_7 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_8 groups;

R_4 is -H, -(C_1-C_{10})alkyl, -C(O)R_9, or -C(O)NHR_9;

R_5 is -H or -(C_1-C_{10})alkyl;

each R_7 and R_8 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, -COR_{10}, -C(O)OR_{10}, -OC(O)R_{10}, -OC(O)OR_{10}, -SR_{10}, -S(O)R_{10}, or -S(O)$_2R_{10}$;

each R_9 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OH, -N(R_{10})$_2$, -CH=NR_{10}, -NR_{10}OH, -OR_{10}, or -SR_{10};

each R_{10} is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R_{11} and R_{12} is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -N(R_7)$_2$, -CH=NR_7, -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)$_2R_7$;

each R_{13} is independently -(C_1–C_6)alkyl, -(C_2–C_6)alkenyl, -(C_2–C_6)alkynyl, -(C_3–C_8)cycloalkyl, -(C_5–C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, CH_2(halo), or -halo;

each halo is independently -F, -Cl, -Br, or -I;

s is an integer ranging from 0 to 4;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

t is an integer ranging from 0 to 2;

p is an integer ranging from 0 to 2;

n is an integer ranging from 0 to 3; and

m is an integer ranging from 0 to 2.

128. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 126 and a pharmaceutically acceptable carrier or excipient.

129. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 127 and a pharmaceutically acceptable carrier or excipient.

130. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 126.

131. A method for treating pain, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 127.

132. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 126.

133. A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 127.